Non-invasive optical imaging of neuropathology in vivo

体内神经病理学的无创光学成像

基本信息

批准号：
7903375
负责人：
Brian J Bacskai
金额：
$ 84.22万
依托单位：
MASSACHUSETTS GENERAL HOSPITAL
依托单位国家：
美国
项目类别：
财政年份：
2006
资助国家：
美国
起止时间：
2006-09-01 至 2012-07-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/7903375
关键词：
3-Dimensional Age Algorithms Alzheimer&apos s Disease Amyloid beta-Protein Angiography Animal Model Animals Antibodies Area Arts Binding Biology Biomedical Engineering Blood - brain barrier anatomy Blood flow Boa Brain Brain imaging Cerebrum Chemistry Computer software Deposition Detection Development Disease Progression Dyes Emerging Technologies Engineering Evaluation Fluorescence Fluorescent Probes Functional Imaging Goals Head Human Image Imaging Device Imaging Techniques Label Lead Life Light Magnetic Resonance Imaging Measurement Metabolism Modeling Mus Natural History Near-Infrared Spectroscopy Neuroanatomy Neurology Non-Invasive Cancer Detection Optical Tomography Optics Outcome Measure Pathology Peptide Hydrolases Positron-Emission Tomography Principal Investigator Property Proteins Psychiatrist Reagent Reporter Research Personnel Resolution Screening procedure Senile Plaques Sensitivity and Specificity Signal Transduction Staining method Stains Structure System Techniques Technology Testing Therapeutic Time Tissues Transgenic Mice experience fluorescence imaging fluorophore gray matter imaging probe in vivo instrumentation molecular imaging mouse model multidisciplinary nervous system disorder neuropathology next generation novel optical imaging optical switch programs protein aggregate reconstruction single photon emission computed tomography software development tumor white matter

项目摘要

DESCRIPTION (provided by applicant): Non-invasive optical imaging capitalizing on the transmissive properties of the near-infrared spectrum is a rapidly evolving molecular imaging approach complementary to MRI, PET, or SPECT. Optical imaging is inexpensive and allows in vivo imaging of intact animals with spatial resolutions less than 1 mm. Significant strides in structural detection of tumors and functional imaging of blood flow, metabolism, and protease activities have recently been accomplished in both animal models and humans. The next generation of optical imaging approaches will depend on novel contrast reagents that specifically identify structures or functions within intact animals. We propose to accelerate the development of optical imaging techniques, as well as to generate novel optical contrast reagents for near infrared molecular imaging. We will modify an existing optical imaging system to optimize the sensitivity and spatial resolution with advances in both hardware and software for intracranial imaging of intact mice. We will also develop a suite of molecular imaging probes that will target specific intracranial structures, with applications for in vivo imaging for a broad range of neurological diseases. We will develop fluorescent probes for non-invasive measurement of grey matter, white matter, cerebral vasculature, and the pathological protein aggregates found in Alzheimer's disease. Successful implementation of these techniques will not only aid in the characterization of the natural history of structural alterations in the brain in a variety of animal models, but will serve as a quantitative end-point for evaluation and screening of therapeutics aimed at ameliorating the progression of disease in animal models. This proposal brings together a multidisciplinary team with a broad range of experience. Principal investigator Brian Bacskai at MGH has extensive experience in optical imaging, in vivo detection of neuropathology and biomedical engineering. The multidisciplinary team includes MIT chemist Timothy Swager, U. Pittsburgh Psychiatrist/Chemist William Klunk, MGH optical engineer David Boas, MGH Neuroanatomist Brad Hyman, and MGH Neuroscientist Steven Reeves. The combined efforts from this project will lead to a new arsenal of molecular imaging tools to exploit the newly emerging technology of NIR spectroscopy.

描述（由申请人提供）：利用近红外光谱的透射特性的非侵入性光学成像是一种快速发展的分子成像方法，与 MRI、PET 或 SPECT 互补。光学成像价格低廉，并且可以对完整动物进行体内成像，空间分辨率小于 1 毫米。最近在动物模型和人类中，肿瘤的结构检测以及血流、代谢和蛋白酶活性的功能成像方面都取得了重大进展。下一代光学成像方法将依赖于特异性识别完整动物内的结构或功能的新型造影剂。我们建议加速光学成像技术的发展，以及生产用于近红外分子成像的新型光学对比试剂。我们将修改现有的光学成像系统，利用完整小鼠颅内成像的硬件和软件的进步来优化灵敏度和空间分辨率。我们还将开发一套针对特定颅内结构的分子成像探针，可应用于多种神经系统疾病的体内成像。我们将开发荧光探针，用于非侵入性测量灰质、白质、脑血管系统以及阿尔茨海默病中发现的病理性蛋白质聚集体。这些技术的成功实施不仅有助于表征各种动物模型中大脑结构改变的自然史，而且将作为评估和筛选旨在改善疾病进展的治疗方法的定量终点。动物模型中的疾病。该提案汇集了一支具有广泛经验的多学科团队。 MGH 的首席研究员 Brian Bacskai 在光学成像、神经病理学体内检测和生物医学工程方面拥有丰富的经验。该多学科团队包括麻省理工学院化学家 Timothy Swager、美国匹兹堡精神病学家/化学家 William Klunk、MGH 光学工程师 David Boas、MGH 神经解剖学家 Brad Hyman 和 MGH 神经科学家 Steven Reeves。该项目的共同努力将产生一个新的分子成像工具库，以利用新兴的近红外光谱技术。

项目成果

期刊论文数量（3）

专著数量（0）

科研奖励数量（0）

会议论文数量（0）

专利数量（0）

Fluorescence lifetime-based optical molecular imaging.

基于荧光寿命的光学分子成像。

DOI：
发表时间：
2011
期刊：
影响因子：
0
作者：
Kumar; Anand T N
通讯作者：
Anand T N

Development and screening of contrast agents for in vivo imaging of Parkinson's disease.

用于帕金森病体内成像的造影剂的开发和筛选。

DOI：
发表时间：
2013-10
期刊：
影响因子：
3.1
作者：
Neal, Krista L;Shakerdge, Naomi B;Hou, Steven S;Klunk, William E;Mathis, Chester A;Nesterov, Evgueni E;Swager, Timothy M;McLean, Pamela J;Bacskai, Brian J
通讯作者：
Bacskai, Brian J

Near-infrared fluorophores containing benzo[c]heterocycle subunits.

含有苯并[c]杂环亚基的近红外荧光团。